PUMA BIOTECHNOLOGY, INC. (PBYI)
PUMA BIOTECHNOLOGY, INC. (PBYI) from its SEC filings: 2025 revenue $228.4 million (-1% vs the year before), net margin 14%, free cash flow $41.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $228.4 million |
| Revenue growth | -1% |
| Net income | $31.1 million |
| Net margin | 13.6% |
| Free cash flow | $41.7 million |
| Diluted EPS | $0.61 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +8% |
| Cash | $36.5 million |
| Long-term debt | $0 |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.